Nucleoside Analogues PhosphorylationNucleoside analogues are cornerstones of current anticancer and antiviral therapies. Antiviral nucleoside analogs inhibit viral replication, whereas anticancer nucleosides inhibit replication of cellular DNA and repair. Nucleoside analogs are inactive prodrugs and their therapeutic efficacy depends on their intracellular phosphorylation.
Cellular deoxycytidine kinase (dCK) provides the first step of activation of highly effective anti-cancer and anti-viral drugs, such as 1-β-D-arabinofuranosylcytosine (araC, aracytidine), 2’,2’difluorodeoxycytidine (dFdC, gemcitabine), β-D-2’3’-dideoxycytidine (ddC). dCK kinase phosphorylates alsounnatural L-nucleosides (e.g., β-L-2’3’-dideoxy-3’thiacytidine, L-SSdC, 3-TC or lamividune). Cellular adenosine kinase (ADK) provides phosphorylation of ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), purine nucleoside analogue with a broad-spectrum antiviral activity. For rapid evaluation of substrate specificy of novel anticancer and antiviral nucleoside analogues NOVOCIB offers For HTS evaluation of ADK activity in lysates, NOVOCIB also supplies ADK Assay Kit. |
Related Links | |
• ADK Assay Kit
• ADK enzyme • dCK Assay Kit • dCK enzyme |